– USA, MA – Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Georges Gemayel, Ph.D. to its Board of Directors effective January 1, 2016. Dr. Gemayel has over 25 years of experience in the global biopharmaceutical industry including management and executive positions at biopharmaceutical companies such as Roche Labs, Genzyme and Altus Pharmaceuticals.
“I am pleased to welcome Georges to Momenta’s Board of Directors during this exciting stage in our Company’s growth,” said Craig Wheeler, President and CEO, Momenta Pharmaceuticals. “We believe his extensive experience in biopharmaceutical product development and commercialization will benefit the Company as we continue to advance our robust product pipeline and work toward our goal of bringing multiple products to market in the coming years.”
Dr. Gemayel has been a consultant for several biotechnology companies and venture capital funds since 2010. Prior to that he was President and CEO of Altus Pharmaceuticals from 2008 to 2009. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation where he was responsible for the company’s worldwide therapeutics businesses. From 1988 to 2003, he held progressively senior roles at Hoffmann La-Roche and Roche Labs. Dr. Gemayel currently serves on the Board of Directors of the publically listed companies Raptor Pharmaceutical Corp. and Supernus Pharmaceuticals and of Dimension Therapeutics, a privately owned company. He is Chairman of the Board of Directors of privately owned biotechnology companies Orphazyme, OxThera, and Enterome Bioscience. He previously served on the Board of Directors of NPS Pharmaceuticals, Prosensa, Adolor Corporation, FoldRx, Epitherapeutics and Altus Pharmaceuticals.
Dr. Gemayel completed his doctorate in pharmacy at St. Joseph University in Beirut, Lebanon, and earned a Ph.D. in pharmacology at Paris-Sud University in Paris, France.
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.